6533b858fe1ef96bd12b65f2
RESEARCH PRODUCT
Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers
Matthias BartneckChristian TrautweinMatthias BarzFrank TackeTwan LammersChristopher Thorsten SchlößerRudolf Zentelsubject
0301 basic medicinemedicine.medical_treatmentGeneral Physics and Astronomy02 engineering and technologyFucoseImmunomodulationMice03 medical and health scienceschemistry.chemical_compoundImmune systemPolysaccharidesmedicineAnimalsHumansGeneral Materials ScienceCell adhesionCells CulturedInflammationBinding SitesbiologyChemistryLiver DiseasesGeneral EngineeringImmunotherapy021001 nanoscience & nanotechnologyDynamic Light ScatteringExtravasationIn vitro3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyBiochemistryConcanavalin ASelectinsbiology.proteinCancer researchCytokines0210 nano-technologySelectindescription
Immunotherapies have the potential to significantly advance treatment of inflammatory disease and cancer, which are in large part driven by immune cells. Selectins control the first step in immune cell adhesion and extravasation, thereby guiding leukocyte trafficking to tissue lesions. We analyzed four different highly specific selectin-binding glycopolymers, based on linear poly(2-hydroxypropyl)-methacrylamide (PHPMA) polymers. These glycopolymers contain either the tetrasaccharide sialyl-LewisX (SLeX) or the individual carbohydrates fucose, galactose, and sialic acids mimicking the complex SLeX binding motive. The glycopolymers strongly bind to primary human macrophages, without activating them, and also to primary human blood leukocytes, but poorly to fibroblasts and endothelial cells in vitro. After intravenous injection in mice, all glycopolymers accumulated in the liver without causing hepatotoxicity. The glycosylated binder most potently targeted resident hepatic macrophages (Kupffer cells) and pro...
year | journal | country | edition | language |
---|---|---|---|---|
2017-08-23 | ACS Nano |